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Summary
Background Azithromycin is a macrolide antibiotic with anti-inﬂ ammatory and immunomodulatory properties. We 
tested the hypothesis that azithromycin would decrease the frequency of exacerbations, increase lung function, and 
improve health-related quality of life in patients with non-cystic ﬁ brosis bronchiectasis.
Methods We undertook a randomised, double-blind, placebo-controlled trial at three centres in New Zealand. Between 
Feb 12, 2008, and Oct 15, 2009, we enrolled patients who were 18 years or older, had had at least one pulmonary 
exacerbation requiring antibiotic treatment in the past year, and had a diagnosis of bronchiectasis deﬁ ned by high-
resolution CT scan. We randomly assigned patients to receive 500 mg azithromycin or placebo three times a week for 
6 months in a 1:1 ratio, with a permuted block size of six and sequential assignment stratiﬁ ed by centre. Participants, 
research assistants, and investigators were masked to treatment allocation. The coprimary endpoints were rate of event-
based exacerbations in the 6-month treatment period, change in forced expiratory volume in 1 s (FEV1) before broncho-
dilation, and change in total score on St George’s respiratory questionnaire (SGRQ). Analyses were by intention to treat. 
This study is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12607000641493.
Findings 71 patients were in the azithromycin group and 70 in the placebo group. The rate of event-based exacerbations 
was 0·59 per patient in the azithromycin group and 1·57 per patient in the placebo group in the 6-month treatment 
period (rate ratio 0·38, 95% CI 0·26–0·54; p<0·0001). Prebronchodilator FEV1 did not change from baseline in the 
azithromycin group and decreased by 0·04 L in the placebo group, but the diﬀ erence was not signiﬁ cant (0·04 L, 
95% CI –0·03 to 0·12; p=0·251). Additionally, change in SGRQ total score did not diﬀ er between the azithromycin 
(–5·17 units) and placebo groups (–1·92 units; diﬀ erence –3·25, 95% CI –7·21 to 0·72; p=0·108).
Interpretation Azithromycin is a new option for prevention of exacerbations in patients with non-cystic ﬁ brosis 
bronchiectasis with a history of at least one exacerbation in the past year.
Funding Health Research Council of New Zealand and Auckland District Health Board Charitable Trust.
Introduction
Bronchiectasis is a disorder characterised by neutrophilic 
airway inﬂ ammation, chronic bacterial infection, and 
recurrent pulmonary exacerbations.1 Patients with bron-
chiectasis can have a disabling cough with production of 
large amounts of sputum, progressive decline in lung 
function,2 impaired quality of life,3,4 and increased 
mortality.5,6 Exacerbations occur at rates of 1·5–6·5 per 
patient per year,7,8 and are associated with an increased risk 
of admission and readmission to hospital, and high health-
care costs.9
The prevalence of bronchiectasis in most adult popu-
lations worldwide is unknown. With the widespread 
availability of modern diagnostic techniques such as high-
resolution CT scanning, bronchiectasis is in creasingly 
being recognised. In the USA, the number of bronchi-
ectasis-associated admissions increased by 2–3% per year 
between 1993 and 2006, and the mean annual rate of 
admission in this period was 16·5 per 100 000 people.9 A 
further study10 showed that the prevalence of bronchiectasis 
increased by 8·7% per year between 2000 and 2007.
Few evidence-based treatments are available for the 
prevention and management of exacerbations and more 
are urgently needed.11 Macrolide antibiotics have anti-
inﬂ ammatory and immunomodulatory prop erties in 
addition to their antibacterial properties.12 In the Eﬀ ective-
ness of Macrolides in patients with BRonchi ectasis using 
Azithromycin to Control Exacerbations (EMBRACE) trial, 
we tested whether azithromycin de creases the frequency 
of exacerbations, increases lung function, and improves 
health-related quality of life in patients with non-cystic 
ﬁ brosis bronchiectasis.
Methods
Study design and participants
We undertook a randomised, double-blind, placebo-
controlled trial at three centres in New Zealand between 
Feb 12, 2008, and Oct 15, 2009. Patients were eligible for 
inclusion in the study when they were 18 years or older, 
had had at least one pulmonary exacerbation requiring 
antibiotic treat ment in the past year, and had a diagnosis 
of bron chiectasis deﬁ ned by high-resolution CT scan. All 
Background 1
EMBRACE Design
Objectives Assess the effect of azithromycin on health-related quality
of life and lung function in patients 18–80 years with
bronchiectasis (diagnosed by CT scan).
Design Multicenter (3), double-blind, placebo-controlled, parallel
group (1:1), 141 pts total.
Intervention 500mg azithromycin capsule vs. placebo, 3 days per week,
for six months.
1◦ Endpoints i) Rate of Event Based Exacerbations (EBEs) over 6 mo.
treatment period;
ii) Change in St. George’s Respiratory Questionnaire (tot.
score); (+ others).
2◦ Endpoints Symptom scores for: sputum purulence, sputum volume,
dyspnoea; (+ others).
Background 2
Exacerbations
I Patients exacerbations and symptom scores recorded prospectively in
patient diaries.
I Each patient-day judged exacerbation or no exacerbation.
I Key symptoms of an exacerbation are
I Sputum volume
I Sputum purulence (colour)
I Dyspnoea (shortness of breath, coughing).
I Two types: Event-based (EBE) and Symptom-based (SBE).
I Ascertainment of EBE requires contact with clinician.
I SBE is determined from patient diary data.
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EBE Incidence
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Figure : Diarized days by Event-based exacerbations status for each EMBRACE location, all
patient-days.
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Goal
Automatic adjudication of symptom-based exacerbations
New Definition of SBEs
I Adjudication of SBEs originally done by manual review of diaries.
I Automation of SBE adjudication presented opportunity to revisit
definition.
I New definition of SBE to be based on a prediction rule validated
against the clinically adjudicated EBEs.
Validated Prediction Rule
I Build a regression model for EBEt using symptom scores and EBE at
times t ∈ [t − δ, t0).
Method 5
Data
I Observed ∼ 50 000 patient-days observed on 141 patients across 3
centres over 6 months.
I Patients rated severity of
I Sputum purulence, sputum volume, dyspnoea
on a validated 5-point scale, 0 “no symptom”→ 4 “very much”.
Table : Example data
Symptoms
Pat. Day EBE SP SV DY SBE
1 0 0 1 1 1 ↑
1 1 1 3 3 4 ↑
...
...
...
...
...
... Adjudicated
1 17 1 2 1 5 ↓
1 18 0 1 0 0 ↓
...
...
...
...
...
... ↓
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Method 6
Goal is a Model for Prediction
I Statistical goal is a model to predict a time-ordered, clustered,
binary outcome, EBEi,t .
I Selected GLM, logit link, random intercepts for patient.
logit Pr(EBEi,t = 1|·) = x′i,tβ + zibi + i,t
bi ∼ Normal(0, τ 2) ⊥ i,t ∼ Normal(0, σ2)
(columns of X are symptom scores and EBEi,t−δ)
ÊBEi,t =
{
1 if P̂r
(
EBEi,t | ·
)
> c
0 if P̂r
(
EBEi,t | ·
) ≤ c
(c chosen such that sensitivity = specificity)
I Design parameters are: X, δ, c.
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Method Overview
1. Build a “retrospective” prediction model for EBEt using
I symptom scores
I observed EBE status at times t ∈ [t − δ, t0).
2. Convert to a “prospective” model for EBEt using
I retrospective design
I predicted EBE status at times t ∈ [t − δ, t0).
3. Estimate its predictive performance.
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Design
I Fixed effect design matrix, X, contains
I patient-specific symptom scores at a contemporaneous time interval,
t ∈ [−a, t0].
I patient-specific symptom scores at an earlier time interval,
t ∈ [−c,−b], a < b < c.
I EBE status at an earlier time point, EBEi,t−δ.
I For any given choice of a, b, c, symptom scores can be averaged, or
not, over the intervals.
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Design
I 72 combinations of δ, a, b, c, and averaging schemes were defined
based on existing “by-hand” adjudication methods.
2︸︷︷︸
contemporaneous
window
× 4︸︷︷︸
earlier
window
× 3︸︷︷︸
δ
× 3︸︷︷︸
avg. schemes
= 72 models
I In-sample predictive performance of each compared using AUC.
Table : Best designs within each avg. scheme.
Avg. Scheme Contemp. Window Comp. Window δ AUC
1 [−3, 0] [−11,−7] 5 0.84
2 [−3, 0] [−11,−7] 10 0.85
3 [−3, 0] [−8,−4] 5 0.97
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Selected Model
I Averaging scheme consists in arithmetic average of symptom scores
over the interval.
I Includes all two-way interactions between EBEi,t−5 and averaged
symptom scores.
ηi,t ≡ logit Pr(EBEi,t = 1|EBEi,t−5,Xi,t , bi )
= β0 + EBEi,t−5×(
SVi,cont. + SPi,cont. + DYi,cont. + SVi,earl. + SPi,earl. + DYi,earl.
)
+ bi + i,t
ηi,t ∈ (−∞,∞), EBEi,t ∈ {0, 1}, t = 0, 1, . . . ,T ,
bi ∼ Normal(0, τ 2) ⊥ i,t ∼ Normal(0, σ2)
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Prospective Prediction
I The selected model is retrospective in that today’s prediction
depends on earlier observed EBEs.
logit Pr(EBEi,t = 1 |EBEi,t−5, ·) = x′iβ + zibi + i,t
I We want a prospective model that uses earlier predictions to make
today’s prediction.
logit Pr(EBEi,t = 1 | ÊBEi,t−5, ·) = w′iβ + zibi + i,t
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A Model for Prediction
Goal
I Recall that our goal is a model for prediction.
I ⇒ propose a model (somehow!).
I Verify it has good predictive power.
Two-fold Cross-validation
I Split data into a training set and a hold-out set for validation.
I Randomly select 70 percent of the patients and allocate all their
observations to the training set.
I The remainder go into the hold-out set.
Method Prospective Prediction 13
Sequential Approach
1. Initialize by generating retrospective predictions, ÊBE
[ret]
i,1 , . . . ,
ÊBE
[ret]
i,5 , using β̂ and threshold, c
[ret], from the retrospective model.
Using the training set:
2. Sequentially generate prospective predictions ÊBE
[pro]
i,6 , ÊBE
[pro]
i,7 , . . . .
I Use “population level” predictions
I Use c [ret] to threshold the predicted probabilities (we have to because
this is the only c currently available).
3. Re-estimate the binary threshold, c [pros], using ÊBE
[pro]
i,t .
Using the hold-out set:
4. Repeat 2 using c [pros].
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Results
Dataset Model c (used) c (Opt.) Sens. (%) Spec. (%)
Training Retro. 0.093 0.093 90 92
Prosp. 0.093 0.048 76 88
Prosp. 0.048 0.048 83 83
Hold-out Prosp. 0.048 — 90 79
I Our prospective SBE predictor,
I misses 10 percent of the EBEs (1 in 10)
I calls an EBE 21 percent of time there isn’t one (1 in 5).
I Relative to using the whole dataset,
I Estimated sensitivity equal,
I Specificity is 86 percent (↓ 13 percentage points).
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Patient-reported Wellbeing
I Ultimately, we’re interested in patient wellbeing, and a
patient-centred measure that is sensitive to changes in physical state.
I Patients also reported wellbeing each day using a 1–5 scale (SGRQ).
I How is our new definition of SBE associated with wellbeing?
I Do we get “closer” to wellbeing with SBE rel. to EBE?
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EBE, SBE, and Wellbeing
I Consider EBE and SBE as “tests” for wellbeing,
I i.e., sens. = Pr(EBE = 1 |WB ≤ 2).
I Wellbeing is dichotomized between 2 and 3.
bad ≡ 1 good ≡ 0
1 2 3 4 5
(so indicator of “bad” wellbeing corresponds to indicator of “bad”
EBE/SBE)
Patient-reported Wellbeing 17
Wellbeing and EBE
EBE wellbeing_leq2
Frequency|
Percent |
Col Pct | 0| 1| Total
---------+--------+--------+
0 | 24274 | 16579 | 40853
| 52.36 | 35.76 | 88.13
| 83.44 | 96.03 |
---------+--------+--------+
1 | 4818 | 685 | 5503
| 10.39 | 1.48 | 11.87
| 16.56 | 3.97 |
---------+--------+--------+
Total 29092 17264 46356
62.76 37.24 100.00
I Spec. = 83%.
I Sens. = 4%.
I Most (96%) episodes
of poor wellbeing do
not correspond to an
EBE.
Patient-reported Wellbeing 18
Wellbeing and SBE
SBE wellbeing_leq2
Frequency|
Percent |
Col Pct | 0| 1| Total
---------+--------+--------+
0 | 17414 | 14567 | 31981
| 40.18 | 33.61 | 73.79
| 63.51 | 91.48 |
---------+--------+--------+
1 | 10006 | 1356 | 11362
| 23.09 | 3.13 | 26.21
| 36.49 | 8.52 |
---------+--------+--------+
Total 27420 15923 43343
63.26 36.74 100.00
I Well . . . we’ve doubled
the proportion of bad
wellbeing days
captured!
I Spec. ↓ 20 percentage
points.
I Work in progress!
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Summary
I Exacerbations are an outcome of interest in the study of
bronchiectasis.
I Ascertainment of event-based exacerbations (EBEs) requires clinical
assessment.
I Symptom-based exacerbations (SBEs) are ascertained from
patient-reported symptom scores and exacerbation history, coded “by
hand”.
I We used logistic regression to develop an “automatic” coding
scheme; changes in symptoms that are associated with changes in
physical state (EBE).
I As a classifier of EBE the performance was quite good (sens. 90%,
spec. 79%).
I Unlcear we moved closer to patient-reported wellbeing (SGRQ)
. . . to be continued.
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